The result supports LKT as a potential treatment to overcome immune checkpoint inhibitor-associated resistance.Clinical trial information: NCT04291079.Enrolled pts (n)ccRCC(N=30)HNSCC(N=9)MEL(N=11)UC(N=11)NSCLC(N=11)Efficacy Evaluable pts1(n)306101111ORR20%33.3%20%9.1%0%PR (n)62210Tumor ...
was given as a monotherapy or in combination with anti–PD-1 or PD-L1 agents in patients with locally advanced or metastatic solid tumors, it was found to be generally well tolerated and to demonstrate early indications of efficacy, according to data from the phase 1 DRAGON tr...
Conclusions As of 26 May 2023, combination treatment of SRK-181 and anti-PD-1 (pembrolizumab) was generally well tolerated with an ORR of 25% and clinical benefit rate of 69% in heavily pre-treated, anti-PD-1-refractory ccRCC patients. Enrollment is ongoing for all cohorts. Reference Yap ...